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Abstract
Background: Large-scale genomic analyses of patient cohorts have revealed extensive heterogeneity between individual
tumors, contributing to treatment failure and drug resistance. In malignant melanoma, heterogeneity is thought to arise as
a consequence of the differentiation of melanoma-initiating cells that are defined by cell-surface markers like CD271 or
CD133.
Results: Here we confirmed that the nerve growth factor receptor (CD271) is a crucial determinant of tumorigenicity, stem-
like properties, heterogeneity and plasticity in melanoma cells. Stable shRNA mediated knock-down of CD271 in patient-
derived melanoma cells abrogated their tumor-initiating and colony-forming capacity. A genome-wide expression profiling
and gene-set enrichment analysis revealed novel connections of CD271 with melanoma-associated genes like CD133 and
points to a neural crest stem cell (NCSC) signature lost upon CD271 knock-down. In a meta-analysis we have determined a
shared set of 271 differentially regulated genes, linking CD271 to SOX10, a marker that specifies the neural crest. To dissect
the connection of CD271 and CD133 we have analyzed 10 patient-derived melanoma-cell strains for cell-surface expression
of both markers compared to established cell lines MeWo and A375. We found CD271+ cells in the majority of cell strains
analyzed as well as in a set of 16 different patient-derived melanoma metastases. Strikingly, only 2/12 cell strains harbored a
CD133+ sub-set that in addition comprised a fraction of cells of a CD271+/CD133+ phenotype. Those cells were found in the
label-retaining fraction and in vitro deduced from CD271+ but not CD271 knock-down cells.
Conclusions: Our present study provides a deeper insight into the regulation of melanoma cell properties and points CD271
out as a regulator of several melanoma-associated genes. Further, our data strongly suggest that CD271 is a crucial
determinant of stem-like properties of melanoma cells like colony-formation and tumorigenicity.
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Introduction
Malignant melanomas originate from the oncogenic transfor-
mation of melanocytes [1] the pigment cells of the skin and the
eyes. These among others stem from a multipotent neural crest
stem cell (NCSC) that expresses the nerve growth factor receptor
CD271 and the SRY-box transcription factor SOX10 [2]. The
latter acts in concert with a well-defined set of growth factors and
inhibitors (reviewed in [3]) to trigger the derivation of melanocytes
from the NCSC. Recent studies may evidence that the sustained
expression of CD271 during melanocyte development may
support the process of melanoma formation [4]. Consistently,
CD271 was recognized recently as a crucial molecule that drives
melanoma initiation and metastasis by a yet unknown mechanism
[5] thus endowing melanoma cells with stem-like properties. Stem-
like features of melanoma cells were additionally associated with
the presence of the glioma and neural stem cell marker CD133
(also known as PROM1) [6,7]. CD133 expression is correlated
with a high tumorigenic and metastatic potential of melanoma
cells and facilitates cell motility [8]. Like CD271 and CD133 in
melanoma-initiating cells, SOX10 expression maintains the
multipotent phenotype of NCSCs [2] and the tumorigenic and
proliferative capacity of melanoma cells [9].
Like their stem cell counterparts in normal tissue, tumor-
initiating cells are capable to self-renew [10] by asymmetric cell
division resulting in the formation of a tumor-initiating cell and
differentiated progeny which have lost the tumor-initiating
potential of the mother cell [11]. In malignant melanomas this
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progeny is characterized by either the melanoma antigens HMB45
and MART-1 [12], the microphthalmia-associated transcription
factor (MITF) or the melanin synthesis controlling enzyme
tyrosinase (TYR). However, besides asymmetric cell division,
label-retention and colony-formation as well as a high cellular
plasticity are determinants of stem-like cells. Cellular plasticity of
tumor-initiating cells represents a proposed mechanism that leads
to intra-tumor heterogeneity as they are thought to be capable to
enter, exit and to re-enter a stem-cell state while changing their
phenotype defined by expression of cell surface markers like
CD271 or ABCB5 [13]. The cellular heterogeneity leads to
variations of cancer cells, residing in a tumor along with stromal
elements that collectively form the microenvironment. Since solid
tumors can be composed of a variety of clones or subpopulations
of cancer cells, these cells may differ among themselves in many
properties, such as growth rate, production and expression of cell
surface markers or sensitivity to therapeutics (chemo, biologic,
radiation).
However, the implementation of markers of melanoma-
initiating cells to determine stem-like properties as well as their
role within a melanoma-associated network is elusive. Here we
uncover the significance of CD271 expression for melanoma cell
tumorigenicity and plasticity and demonstrate a CD271-depen-
dend regulation of the neural crest specifier SOX10 and the
connection to CD133. Further we show that both CD271+ and
CD133+ cells exhibit plasticity allowing the transition of CD271+
cells to adopt a CD271+/CD133+ phenotype and the transition of
CD1332 cells to form CD133+ tumors.
Results
Expression of CD271 is crucial for the tumorigenic
growth of melanoma cells
Melanoma cells expressing the neural crest stem cell marker
CD271 are considered as the crucial cellular compartment capable
of tumor initiation and differentiation [14,15]. To investigate the
role of CD271, we performed a stable shRNA-mediated knock-
down in a patient-derived melanoma cell strain using different
shRNA plasmids (#2, #3 and #4). Silencing of CD271 induced a
change in morphology from spindle-shaped to epithelial-like as
indicated by a change in the localization of CD166 and led to a
strong reduction of proliferation (Figure S1A–B). To investigate
the effect of CD271 knock-down on tumorigenicity we injected
16106 of either shRNA#4 transfected (CD271k.d.) cells or cells
transfected with a control shRNA (shCtl.) into NSG mice (NOD/
SCID mouse strain with a lack in IL2 receptor gamma chain).
After six weeks no tumors were observed in CD271k.d. cell
recipient mice (Figure 1A), whereas shCtl. cells prompted tumor
development (Figure 1B–C). Xenografted tumors displayed
expression of CD271 as well as melanoma differentiation markers
TYR and MITF (Figure 1D). To identify putative CD271
dependent regulatory mechanisms we compared CD271k.d. cells
and shCtl. cells in a genome-wide expression profiling. We
identified 68 down-regulated (ratio ,0.05fold) and 55 up-
regulated genes (ratio .20fold), (Figure S1C). We focused on 10
of the most important and significantly regulated (limma_FDR#
0.005) genes that are known to be crucial for melanoma
development. We found 9 genes strongly down-regulated like
SOX10 (31-fold), ERBB3 (9-fold), IGFBP2 (7-fold), RHOJ (6-fold),
FST (4-fold), SOX2 (3-fold), GLI-2 (3-fold) and MITF (1.4-fold)
upon CD271 knock-down (Figure 1E). With CD133 differentially
expressed, our screen identified another putative marker of
melanoma-initiating cells. By qPCR we confirmed the differential
expression of a majority of these genes in CD271k.d. cells and
prompted an inverse correlation of CD271 and CD133 mRNA
expression levels. Increased levels of CD133 mRNA by three
different shRNA sequences as well as the strong decrease of SOX10
and the neural crest marker FOXD3 [16] was verified (Figure 1F).
Immunofluorescence microscopy verified the down-regulation of
SOX10 and FOXD3 in the majority of cells (Figure S1D).
Western blot for CD271 and SOX10 further confirmed the loss of
these markers (Figure S1E). The inverse correlation of CD271 and
CD133 was further observed by over-expression of CD271
(CD271exo) which led to a significantly decreased level of
CD133 (Figure S1F). We also observed the inverse correlation of
CD271 and CD133 in MeWo cells. However, in these cells we
verified the regulation of some but not all CD271-associated genes
e.g. FOXD3 and SOX10 by qPCR and immunofluorescence
microscopy, respectively (Figure S2A–B). Further we observed a
mutually exclusive expression of SOX10 and CD166 in MeWo
cells. Those cells that escaped stable selection following transfec-
tion with shRNA#4 retained SOX10 expression (Figure S2C). To
elucidate the overall effect of the CD271 knock-down we
performed gene-set enrichment analysis (GSEA). GSEA revealed
a neural crest stem cell (NCSC) signature of shCtl. cells that was
lost by knock-down. The NCSC-signature among others com-
prised those genes we found strongly down-regulated in CD271k.d.
cells like SOX10, ERBB3 and MITF but also SNAI2 and SEMA3C
(Figure 1G). These data suggest CD271 as a determinant of
properties of melanoma-initiating cells and melanoma cells.
Commonly, tumor-initiating cells evade apoptosis. Therefore we
asked whether down-regulation of CD271 in melanoma cells may
affect levels of anti-apoptotic genes like cIAP-1, cIAP-2 and BCL-2
(reviewed in [17]). Indeed, we found intensely decreased levels of
these anti-apoptotic genes upon silencing of CD271 (Figure S2D).
In addition, we observed an increased frequency of cells with
DNA-damage as determined by immunofluorescence microscopy
for phosphorylation of histone H2AX (cH2AX) [18], (Figure S2E).
However, we did not observe apoptotic cells by cleavage of
caspase-3 in knock-down cells (data not shown).
CD271+ and CD133+ melanoma cell sub-sets exhibit in
vivo plasticity
Our gene expression data albeit on transcriptional level, suggest
a connection of CD271 and CD133. To figure out a potential
relationship of both markers we have analyzed the cell surface
expression of CD271 and CD133 of 10 patient-specific melanoma
metastases-derived cell strains as well as cell lines MeWo and A375
by flow cytometry (Figure S3A–E). CD271+ cells were observed in
6/10 patient-derived cell cultures, in A375 and MeWo cells
whereas a strong expression of CD133 was observed in just 3/12
cell strains. Among these cell strains we observed a strong variety
in the number of cells expressing CD271 or CD133, respectively.
As cells positive for CD271 or CD133 have been reported to be
the tumor-initiating fraction of melanoma we asked if these sub-
populations differ in terms of their capacity to form differentiated
tumors. In order to determine the tumorigenic potential of both
cellular sub-sets we FACS-isolated cells with a high expression of
CD271 (Figure 2A) or positive or negative for CD133 (Figure S3F)
from cell cultures, respectively. Then, up to 16105 cells sorted or
unsorted for CD133 and different cell numbers of CD271+ cells
(105,106) were injected into NSG mice. Fifty-seven days after
injection all cell populations gave rise to tumors expressing the
melanoma marker HMB45. We observed expression of CD133 in
all tumors irrespective of the initial enrichment of injected cells for
CD271 or CD133 expression (Figure 2B). Within the areas of
CD271+ or CD133+ expressing cells we also observed a sub-set of
CD271+/CD133+ positive cells (Figure 2C). Following injection of
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Figure 1. Expression of CD271 in melanoma cells is a crucial determinant of proliferation and tumorigenicity. (A) Absence of
subcutaneous tumors 45 days after injection of 16106 CD271 knock-down (CD271k.d.) cells into NSG mice. Cells were stably transfected with
shRNA#4. (B–C) Simultaneous injection of cells stably transfected with a shRNA control plasmid (shCtl.) led to proper formation of tumors (arrows in
B). Tumor growth is shown as mean values6 SD of biological triplicates. (D) Tumors of (B) showed expression of CD271, MITF and TYR. H&E indicates
tumor histology. (E) Heat map of 10 significantly regulated melanoma-associated genes selected from a genome-wide expression profiling. Different
splice forms of ras homolog family member J (RHOJ), v-Erb-B2 erythroblastic leukemia viral oncogene homolog 3 (ERBB3), SRY-box 2 (SOX2) and
follistatin (FST) are included. Independent biological triplicates of either CD271k.d. cells or shCtl. cells were analyzed. Up-regulated or down-regulated
genes are indicated in red or blue, respectively. (F) Validation of genome-wide expression profiling by qPCR for the regulation of CD271, CD133,
SOX10, SOX2, ERBB3, insulin-like growth factor binding protein 2 (IGFBP-2), GLI-family zinc finger 2 (GLI-2), RHOJ and forkhead-box D3 (FOXD3) as an
additional gene in patient-derived melanoma cells stably transfected with shRNA plasmids #2, #3 or #4 (CD271k.d.). Expression levels of shRNA
control (shCtl.) cells and CD271k.d. cells are shown as DDCT values normalized to b-actin and related to shCtl. cells as mean values 6 SD of biological
triplicates. *p#0.05; ***p#0.001 (t-test). The scale is logarithmic (log). (G) Comparison of data sets of shCtl. and CD271k.d. cells with data sets of
human embryonic stem cell derived neural crest stem cells (NCSC) [50] by gene-set enrichment analysis (GSEA). GSEA revealed the presence of a
NCSC-specific gene signature in shCtl. cells that is lost upon CD271 silencing (non-NCSC signature). Genes found in the signature among others are
CD271, ERBB3, SOX10, microphthalmia-associated transcription factor (MITF), snail homolog 2 (SNAI2) and semaphorin 3C (SEMA3C).
doi:10.1371/journal.pone.0092596.g001
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105 cells of each fraction we found no significant differences in
tumor volumes of either CD1332 and CD133+, unsorted or
CD271+ cells, respectively, suggesting a similar tumorigenic
capacity of all cellular fractions (Figure 2D and Table S2). By
quantitative RT-PCR of differentiation markers MITF-M,
MART-1 or TYR we confirmed the in vivo differentiation potential
Figure 2. CD271+ and CD133+ melanoma cells hold comparable tumor-initiating capacities. (A) Flow cytometry of enriched CD271+ cells
show a high content of CD271 expressing cells before transplantation. (B) Immunofluorescence analysis and immunohistochemistry on paraffin
sections (2 mm) of tumors derived from 16105 of either CD271+, CD1332, CD133+ or unsorted cells for CD133 (upper row) and HMB45 (center row),
respectively. A representative tumor out of n = 3 is shown. H&E shows histological morphology of tumors (lower row). Haematoxylin served as
counter stain for HMB45. Bar size is 50 mm. (C) Immunofluorescence analysis for CD271 and CD133 on sections of tumors described in (A) showing co-
localization and discrete expression of both markers. Scale bars indicate 50 mm. Nuclei were stained with DAPI (blue). (D) Growth of tumors following
injection of 16105 of either CD271+, CD1332, CD133+ or unsorted cells was monitored for 57 days. Tumor volumes are shown as mean values6 SD of
biological triplicates. Growth of 106 of CD271+ cells is not shown. (E) Comparison of mRNA expression levels of either CD271+ cells with respective
xenograft tumors derived from injection of CD271+ cells at different cell numbers (105, 106; left chart) or comparison of CD133+ cells with tumors as
pointed (right chart). Expression in CD133+ cells was compared to xenograft tumors shown in (B) derived from injection of 105 of CD1332, CD133+ or
unsorted cells. mRNA expression levels of CD271, CD133, SOX10, MITF, MART-1 and TYR were determined by qPCR as indicated. Expression levels
reveal the independence of the in vivo differentiation capacity of melanoma cells from the initial cell number or the cells phenotype. Shown are DCT
values normalized to b-actin as mean value 6 SD of biological triplicates. *p#0.05; **p#0.01 (t-test).
doi:10.1371/journal.pone.0092596.g002
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of cell fractions enriched for either CD271 or CD133, respectively.
The expression of differentiation markers was only marginally
dependent from the number of injected cells (Figure 2E). qPCR
further revealed increased levels of SOX10 in developed tumors
compared to levels in CD271+ cells prior injection. Compared to
CD133+ cells, qPCR showed lower basal levels of differentiation
markers MART-1 and MITF-M in CD271+ cells.
The label-retaining compartment harbors cells with
different phenotypes
To find out if CD271+/CD133+ cells can be maintained in cell
culture, we analyzed low passage bulk cell cultures for co-
expression of both markers by flow cytometry. We found a
relatively high amount (12.1%62.7 and 0.14%60.05) of
CD271+/CD133+ cells in cell cultures of Mel9-1 and Mel4-7,
respectively (Figure 3A). Immunofluorescence analysis showed co-
localization as well as discrete localization of CD271 and CD133
(Figure 3B and S4A).
Asymmetric cell division and differences in doubling times may
commonly guide to cellular heterogeneity. As the ratio of CD271+
and CD133+ cell populations remained stable we measured the
retention of the fluorescent lipophilic dye PKH26, which should
identify slowly dividing cells. The majority of initially labeled cells
lost the dye within 5–7 days. However, 7 days post labeling flow
cytometric analysis revealed a small sub-set of label-retaining cells
that we subsequently isolated by FACS and analyzed the
expression of CD271 and CD133 of recovered cells (Figure 3C).
We observed label-retention for up to 14 days after sorting (Figure
S4B–C). Dye-retaining Mel9-1 cells had either a CD271+/
CD133+ (37.7%67.9) or CD133+/CD2712 (45.3%614.2) phe-
notype and were observed at lower frequency (8.1%63.2) with a
CD271+/CD1332 phenotype (Figure 3C). In a second cell strain
with low expression of CD133, the majority of dye-retaining
Mel4–7 cells was CD271 positive (13.3%64.0) and only a minor
fraction was double positive (0.4%60.04) or positive for CD133
(1.3%60.2) (Figure 3D). However, we also observed negative cells
in the label-retaining fractions of both cell strains as compared to
isotype control (Figure S4D). Analysis of Mel9-1 cells with a lower
Figure 3. The label-retaining melanoma cell-fraction comprises CD271/CD133 double positive cells. (A) Co-expression of CD271 and
CD133 in melanoma cell cultures shown by flow cytometry. The double positive fractions are highlighted and indicated as % 6 SD of biological
triplicates. (B) Immunofluorescence microscopy for co-expression of CD271 and CD133 in cell cultures shows a discrete or simultaneous expression of
these markers. Scale bars indicate 50 mm. Nuclei were stained with DAPI (blue). Representatives of n= 5 are shown. (C–D) Isolation of highly
fluorescent cells that retained the lipophilic dye PKH26 of two melanoma cell strains (Mel9-1 and Mel4-7, left panels) by FACS, 7 days after labeling.
PKH26high fractions are indicated as % 6 SD of n = 3 independent FACS experiments. Confirmation of isolated, dye retaining fractions for presence of
CD271+ and CD133+ cells by co-labeling and flow cytometry (right panels). Analysis shows the presence of cells with discrete and co-expression of
markers. Representative plots indicate fractions as % 6 SD of n= 3 independent experiments. (E) Analysis of isolated dye-retaining cells 7 days after
sorting supports the co-localization of CD271 (green) and PKH26 (red, white arrows, first panel) or co-expression of CD271 (red) and CD133 (green)
(panels 2–4). (F) Co-localization of CD271 (green) and PKH26 (red, white arrows, first panel) and low expression of CD133 in Mel4-7 cells. Scale bars
indicate 50 mm. Nuclei were stained with DAPI (blue). Representatives of n = 3 are shown.
doi:10.1371/journal.pone.0092596.g003
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retaining capacity (shown in purple) revealed a reduced expression
of CD271 (0.61%, data not shown) and increased fraction of
negative cells (60.2%, data not shown). Mel4–7 cells with a lower
retaining capacity have not been analyzed. Immunofluorescence
analysis of dye-retaining Mel9-1 cells grown for 7 days after sorting
confirmed the robust expression of CD271 and CD133 (Figure
3E), whereas the majority of dye-retaining Mel4–7 cells was
CD271+ but extremely rare for expression of CD133 (Figure 3F).
The isolation of cells in three phenotypes CD271+/CD1332,
CD133+/CD2712 and CD271+/CD133+ by dye retention
suggests these cells as part of the slow-dividing melanoma cell
fraction.
CD133+ melanoma cell cultures comprise both
asymmetrically and symmetrically dividing cells
Considering our previous findings, we next analyzed the mode
of cell division by immunofluorescence microscopy. As CD133
expression was linked with asymmetrical division of glioma cells
[19], we expected the number of asymmetrically dividing
melanoma cells to be highest in CD133+ enriched or double
positive cells. In CD133+ enriched cells we observed a sub-set of
CD271+/CD133+ (16.0%67.4) (Figure 4A). We next investigated
the distribution of CD271 and CD133 in dividing cells of the
CD133+ fraction and observed the asymmetrical distribution of
CD133 but not CD271 predominantly in CD133+ cells (Figure
4B). In the CD133+ fraction, asymmetric cell division, although
rare, may be responsible for the observed cellular heterogeneity.
Cells that underwent asymmetrical cell division were further
evident in a minority of unsorted cells as indicated by label
retention (Figure 4C). However, the vast majority of unsorted cells
underwent symmetric cell division (Figure 4D).
Development of CD133+ cells in vitro depends on growth
factor conditions
CD133 and CD271 double positive cells were frequently
observed next to CD271 single positive cells in xenograft tumors.
Therefore, we asked whether these cells could develop from
CD271+ cells and if they are capable of generating cellular
heterogeneity in vitro. Cells were cultivated in hESC-medium in
presence or absence of fibroblast growth factor 2 (FGF2).
Cultivation of cells in absence of FGF2 for five days changed
the ratio between CD271 and CD133 expressing populations
(Figure 5A). Flow cytometry revealed an increase of 3.6% (60.3)
CD133+ cells in hESC-medium without FGF2 compared to
supplemented media (Figure 5B). In addition, the relative amount
of CD271-expressing cells was slightly increased in absence of
FGF2, but remained unchanged in its presence (Figure 5C). Cells
cultivated in hESC-medium in absence of FGF2 formed round-
shaped colonies within 2 days and were growth deficient.
Proliferation of cells was only marginally increased by FGF2.
Subsequently colonies displayed high expression of CD133 and
CD271 (Figure 5D–E).
Figure 4. Asymmetrically dividing cells are CD133+ or double positive. (A) Flow cytometry for CD271 and CD133 in CD133+ enriched cells.
Results depict the presence of single and double positive cells. The experiment was carried out in independent biological triplicates, a representative
example is shown. (B) Distribution of CD271 and CD133 in symmetrically and asymmetrically dividing CD133+ cells detected by immunofluorescence
microscopy for both markers. (C) Asymmetric cell division in unsorted cells is illustrated by the asymmetrical retention of PKH26. (D) Symmetric cell
division is demonstrated by the symmetric orientation of microtubules indicated by a-Tubulin staining (red) and symmetrical distribution of CD133
(green). Scale bars indicate 50 mm. Nuclei were stained with DAPI (blue).
doi:10.1371/journal.pone.0092596.g004
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The formation of CD133 positive cells in vitro is
associated with expression of CD271
To elucidate if the formation of CD133 expressing cells depends
on the presence of CD271, we analyzed the effect of shRNA
mediated CD271 knock-down on the ability to (re)gain CD133
expression in the absence of FGF2. We found that the competence
of cells to form CD133+ colonies is lost upon knock-down of
CD271 but was not affected in shCtl. cells. The latter one
displayed a comparable colony forming capacity to Mock cells
(Figure 5F). To find out further, if CD271+ cells could
spontaneously convert into CD133+ cells, we enriched CD271+/
CD1332 Mel9-1 cells to a yield of 72.7% (Figure S5A). After 3
days of cultivation we performed immunofluorescence microscopy
(Figure S5B) and calculated the ratios for CD271 (85%) and
CD133 (34.2%65.9) cells (Figure S5C). The majority of CD133+
cells was also positive for CD271 (CD271+/CD133+).
As we suppose the derivation of CD133+/CD2712 cells from a
CD271/CD133 double positive population, we have analyzed
double positive sorted cells 3, 5 and 7 days after isolation (enriched
to 93.1% purity; data not shown) for the ratios of CD271+/
CD133+ and CD2712/CD133+ cells, respectively. Although the
CD271+/CD133+ sub-population remained stable for 3 days
(90.0%60.8) we did observe a sub-population of CD133+ cells
(6.8%60.6) that significantly increased after 5 days (17.2%61.6)
and 7 days (26.2%60.9), (Figure S5D–E). Sorted cells were
subjected to PKH26-labeling. The vast majority of cells retained
the dye after 3 days of cultivation but only a small fraction was
highly label retaining after 7 days (Figure S5F). We verified these
findings independently with Mel4-7 cells by confirming that cells
Figure 5. Melanoma cells can adopt a CD133+ phenotype by changes of extracellular cues. (A) Proposed model of phenotypical
transitions of melanoma cells in dependence of FGF2. In this model, a CD271+/CD1332 cell could become CD271+/CD133+. In a second step, this cell
may convert into a CD2712/CD133+ cell. (B–C) Unsorted melanoma cells were grown in standard (Q263) or human embryonic stem cell (hESC)-
medium in absence or presence of FGF2 for 5 days. The amount of CD271 and CD133 positive cells was determined by flow cytometry. Bar graphs
indicate the amount of CD133+ or CD271+ fractions in % 6 SD of biological triplicates. (D) Immunofluorescence microscopy of untransfected (Mock)
cells cultured either in Q263 (upper row) or hESC-medium in absence of FGF2 (lower row) for CD271 (red) and CD133 (green). Double positive
colonies are shown in the bordered area and in the magnification. Scale bars indicate 50 mm. (E) Growth of melanoma cells is shown as cell counts6
SD of n= 3 experiments. 16105 cells were plated initially and cultured for 5 days under different conditions as indicated. *p#0.05; **p#0.01 (t-test).
(F) Immunofluorescence microscopy of shCtl. and CD271k.d. cells grown under colony-forming conditions indicating the formation of CD271+/CD133+
colonies by shCtl. cells but not CD271k.d. cells. Phase contrast (PH) depicts cellular morphology. Scale bars indicate 50 mm. Nuclei were stained with
DAPI (blue). Representatives of biological triplicates are shown.
doi:10.1371/journal.pone.0092596.g005
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sorted for either CD271+/CD1332 or absence of both markers
(CD2712/CD1332) gave rise to CD271+, CD271+/CD133+ and
CD133+ cells (Figure S6A–B). Sorted cells were clearly morpho-
logically distinct from unsorted cells with an epithelial-like and
cluster-forming morphology of CD271+/CD1332 cells and a
spindle-like morphology of CD2712/CD1332 cells (Figure S6C).
The conversion of CD271+/CD1332 sorted cells towards cells
showing a distinct or double expression of these markers was
further verified by immunofluorescence microscopy (Figure S6D).
These data strongly suggest CD271 as to be responsible for colony-
formation and the association of this molecule with melanoma cell
plasticity.
To elucidate a potential mechanism which may trigger the loss
of CD271 expression hence the phenotypic conversion of cells
from CD271+/CD1332 to CD133+/CD2712, we tested the effect
of TGFb2 on shCtl. cells. TGFb is known to epigenetically modify
the expression of CD133 and reduce the level of SOX10 during
the derivation of mesenchymal progenitors from neural crest stem
cells [20]. While CD133 expression was not induced (Figure S6E),
we observed activation of the TGFb-signaling pathway as
reasoned by an increased frequency of cells expressing pSmad2
after treatment of cells for 3 days while a strong reduction of
SOX10 expression was confirmed by immunofluorescence
microscopy.
CD271+ cells show an undifferentiated phenotype
Our in vitro data demonstrate a predominance of CD271 but a
minor appearance of CD133 expressing cells. To dissect whether
the observed distribution of both cellular sub-sets was due cell
culture conditions that selected for robust cell types exhibiting
higher survival and proliferative capacity or can also be found in
patient-derived tumors, we have investigated the distribution of
CD271 and CD133 positive cells in 16 patient-derived metastases.
We found that CD271 was expressed in all tumors investigated,
independent of the origin of the primary tumor and the location of
the respective metastasis (Figure S7A). Areas positive for CD271
were shaped nodule-like with clear boundaries. We did not
observe infiltration into the surrounding tissue. Expression of
CD271 and of the differentiation markers TYR, HMB45 and
MITF was mutually exclusive (Figure 6A and Figure S7B–C). We
did not observe a co-expression of CD271 and CD133 in these
tumors (Figure 6B) as expression of CD133 was limited to regions
positive for the differentiation marker MART-1 (Figure 6C).
These observations support our in vitro data and the finding of a
CD271-dependent stem-like state found by GSEA thus suggest
CD271 as a predominant molecule in malignant melanoma.
Heterogeneity among melanoma metastases is
conserved in xenograft tumors
We further investigated the heterogeneity of patient-derived
metastases (PM), PM-derived xenograft tumors (PMX) and in vitro
established PM-derived cell strains (PMC) as well as a PMC-
derived xenograft tumor, respectively (Figure 6D) by qPCR.
Analysis of mRNA expression levels of CD271, CD133, ABCB5,
SOX2 and melanoma markers SOX10, NES and TYR, MART-1
and MITF-M revealed a strong heterogeneity among the PM
tissue samples (Figure 6E). However, we observed comparable
expression levels between patient-derived metastases and their
respective xenograft tumors in 3 patients (T20/19; T20/03; T20/
18). By qPCR, we found CD271 expressed in all tumors
investigated albeit in one patient only at low level (T20/03).
Immunohistochemistry for CD271 and MITF of PM and PMX of
patients T20/19 and T20/20 demonstrated comparable hetero-
genic patterns of expression (Figure S8A). Additionally, xenograft
tumors of unsorted cultured cells (PMCX) of patient T20/02
revealed a comparable heterogeneity in terms of CD271 and
MITF expression as found in the primary metastasis (Figure S8C).
Even though we observed in part strong variations of marker gene
expression of metastases-derived cell strains established from
patients’ tumors (T20/03, T20/14 and T20/17–20) in compar-
ison to PM. However, expression patterns found in PMC were
comparable to established cell lines A375 and MeWo. These data
demonstrate the persistence of CD271+ cells in metastases-derived
xenograft tumors as well as in tumors of cultured cells.
Discussion
The fact that melanocytes or melanoma cells express genes that
can be similarly found in their developmental ancestor, the neural
crest stem cell (NCSC), may implicate commonalities in the
regulation of cellular properties.
Here, we deciphered novel connections of CD271 with known
melanoma-associated genes and demonstrated that expression of
CD271 determines specific properties of melanoma cells and
melanoma-initiating cells like proliferation, cellular heterogeneity
and tumorigenicity. We found, that CD271 knock-down abolished
the capacity of melanoma cells to form heterogeneous tumors most
likely due to down-regulation of mediators of melanoma invasion
and metastasis (GLI-2 [21], SOX2 [22] and ERBB3 [23]),
angiogenesis (IGFBP-2 [24]), proliferation (FST [25] and MITF)
or chemoresistence (RHOJ [26]). In addition, GSEA revealed that
some of these genes are crucial for NCSC maintenance and
migration, like SOX10 and SNAI2 or SEMA3C [27], respectively.
We found SOX10 as one of the most down-regulated genes in
CD271k.d. cells. As both CD271k.d. cells and SOX10k.d. cells that
were analyzed prior by Shakova et al. [9] were unable to induce
tumor formation in a mouse model system, we strongly suggest
that CD271 acts in concert with or via SOX10 to regulate
melanoma cell properties e.g. tumorigencity. This idea is
underpinned by the finding of a set of 271 overlapping genes
including 65 genes as commonly down-regulated and 145 genes as
commonly up-regulated, respectively (Figure 7A). Among the
down-regulated genes, we found MITF which controls prolifera-
tion and invasiveness of melanoma cells [28] and the endothelin
receptor b (EDNRB) which is strongly associated with melanoma
development [29] and central nervous system directed metastasis
[30]. We also found the bona fide driver of melanoma metastasis
and invasion NEDD9 [31] as well as DEPDC1 and CDCA3, genes
involved in progression of bladder cancer [32] or enhanced
proliferation [29]. Additionally, we found mediators of the NFkB
pathway among those repressed by SOX10 and CD271 (Figure
7B). Among the commonly regulated genes our meta-analysis
identified 52 independently regulated genes and 60 reverse
regulated genes like NAV3 or MSH5 (data not shown). However,
genes belonging to either of the groups have not been analyzed in
more detail, yet. Although CD271 as a member of the TNF-
receptor family should lead to activation of the NFkB pathway this
pathway seems to be inactive in CD271+ melanoma cells and is
activated when the receptor is lost.
SOX10 is known to act as a specifier of neural crest derivatives
[30,33] and directly regulates melanoma associated genes like
ERBB3 [34], EDNRB [35] and MITF [36]. Further, CD271
expression was reduced in SOX10k.d. cells, suggesting a mutual yet
unknown regulation. Our findings confirm previous observations
regarding the role of CD271 and SOX10 in melanoma cells
[14,15]. However, within these studies a connection of CD271
with other melanoma-associated genes has not been analyzed. To
gain further insight into a potential regulatory network connecting
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CD271 and SOX10 we performed GSEA and qPCR analysis. We
confirmed potential transcriptional regulators of SOX10 expres-
sion like SOX8, MYB, ETS1, AP2 (TFAP2A and TFAP2C)
identified previously by Betancur et al. as well as mediators of
WNT and NFkB signaling like TCF4 and NFkB1, respectively.
Although binding of SOXD proteins SOX5 and SOX6 was found
by in silico analyses only, the significance of especially SOX8, MYB
and ETS1 for SOX10 expression has been clearly demonstrated in
Figure 6. CD271 is a predominant marker of malignant melanoma. (A) Immunohistochemistry (IHC) of CD271 and melanoma differentiation
markers TYR, HMB45 and MITF of a representative melanoma metastasis (skin). The mutually exclusive expression of CD271 is marked by the red
dashed line. Haematoxylin was used as a counter stain in IHC and H&E discriminates differentiation marker positive cells with large nuclei from
negative cells with small nuclei. Scale bars indicate 50 mm. (B) Immunofluorescence microscopy of serial sections of a hepatic metastasis (patient T20/
15) shows expression of CD271 and absence of CD133. (C) Co-expression and membranous localization of CD133 and the melanoma antigen MART-1
of a representative out of 16 tumors. Scale bars indicate 50 mm. Nuclei were stained with DAPI (blue). (D) Illustration of patient-derived melanoma
metastases (PM) derivatives: PMX, PM derived xenografted tumors; PMC, PM derived established cell strains; PMCX, PMC derived xenograft tumors.
(E) Roundup of qPCR results of PM, PMX and PMC. Shown are the expression levels of CD271, CD133, ABCB5, SOX10, SOX2, NES, TYR, MART-1 and MITF
(MITF-M) (n = 6). The color code indicates high (red) or median (yellow) expression or low/absence (green). A375, MeWo and human melanocytes
served as controls (metastases of SKIN = cutaneous; PUL = pulmonary/lung and LN = lymph node).
doi:10.1371/journal.pone.0092596.g006
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Figure 7. CD271 and SOX10 are main regulators of a melanoma-associated signaling network. (A) Venn-diagram depicting the meta-
analysis of genes differentially regulated in shCtl. vs. CD271k.d. cells (green) and a data set of shCtl. vs. SOX10k.d. cells (red) [9]. The analysis revealed
271 shared regulated genes among them 65 were found as commonly down-regulated (ratio ,0.75) and 145 as commonly up-regulated (ratio .
1.33). (B) Model of a yet unknown signaling mechanism that leads to activation of a SOX10-dependent network triggered by CD271. The scheme
depicts several genes we found regulated by CD271/SOX10 in (A). Up-regulated genes were representatives of the NFkB family e.g. baculoviral IAP
repeat containing 3 (BIRC3), FOS-Like antigen 2 (FOSL2), interleukins 6 and 8 (IL6/8), SRY-box transcription factor 9 (SOX9) and the nuclear factor of
kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA). Down-regulated genes were the microphthalmia-associated transcription
factor (MITF), endothelin receptor b (EDNRB), neural precursor cell expressed, developmentally down-regulated 9 (NEDD9), DEP domain containing 1
(DEPDC1) and cell division cycle associated 3 (CDCA3). (C–D) Comparison of data sets of shCtl. and CD271k.d. cells with data sets of either a whole-in
situ hybridization study in Xenopus [51] or a RNAse-protection screen for AP2a binding sites [52] by gene-set enrichment analysis (GSEA). GSEA
revealed the presence of TCF4 and TFAP2A (AP2a) regulated genes in shCtl. cells. The TCF4 and TFAP2A signatures are lost upon CD271 silencing.
Beside known WNT/TCF4 target genes MITF, DCT and FST (Follistatin), SOX5, SOX6 and NEDD9 were identified (first panels). GSEA for putative AP2a
regulated genes revealed SOX10, POU3F2 and SOX5 enriched in shCtl. cells. (E) Analysis of mRNA expression levels of modifiers SOX5 and SOX6 and
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chicken embryos [37]. In addition, the expression of SOX10 was
shown to rely on canonical WNT signaling in Xenopus embryos
[33] and is modified by SOX5 in a complex fashion [38]. By
GSEA we found genes regulated in a TCF4-dependent manner
lost in the CD271k.d. cells (Figure 7C). Among known targets of
WNT-signaling like MITF [39] and Follistatin (FST) [40], we
found NEDD9 a gene we observed previously by meta-analysis
and SOX5 and SOX6 (Figure 7D). SOX10, Brn2 (POU3F2) and
SOX5 among others were identified in the group of TFAP2A
target genes. However, we did not observe a clear discrimination
of genes enriched in shCtl. cells and those enriched in CD271k.d.
cells, suggesting a minor role of TFAP2A in the CD271-dependent
regulation of SOX10. Finally, we have analyzed expression levels
of putative modifiers and inducers of SOX10 expression by qPCR
and found a strong and significant down-regulation of SOX5,
SOX6, SOX8 and TFAP2C (AP2c), a moderate down-regulation
of ETS1, TFAP2A (AP2a) and NFkB1 as well as a slight up-
regulation (,2fold) of MYB (Figure 7E). In summary, the
regulation of SOX10 expression in melanoma is supposedly
comparable with the mechanism that controls SOX10 during
development and specification of the neural crest. Therefore,
CD271 may be involved in the regulation of different pathways
like WNT, NFkB and activation of AP2 (Figure 7F) controlling
SOX10 in a direct or indirect fashion. Although we are unable to
dissect the connection of CD271 and SOX10, yet our study
provides a deeper insight in the CD271-dependent signaling
network and reveals that this network comprises several genes
known as drivers of melanoma progression and metastasis.
Besides the direct correlation of CD271 and SOX10, we found
in our present study, that expression of CD133, at least in part,
was dependent from the level of CD271. We observed CD133 up-
regulated in CD271k.d. cells of a patient-derived melanoma cell
strain by genome-wide expression profiling and qPCR. In
opposition, the over representation in CD271exo cells led to
down-regulation of CD133. As we could confirm the correlation of
CD271 and SOX10 or CD133 in MeWo cells a regulation of both
markers by a CD271-dependent signaling mechanism seems very
likely. However, increased cell surface levels of CD133 were not
observed in CD271k.d. cells.
Changes in gene expression upon down-regulation of CD271
not only affect melanoma cell properties but may also induce a
cell-lineage switch from neural-like to mesenchymal-like. Interest-
ingly, we found TGFb-induced genes enriched in CD271k.d. cells
by GSEA (Figure S9A). TGFb-signaling is known to suppress
SOX10 expression and was shown to induce CD133 expression by
down-regulation of DNA-methyltransferases 1 and 3 b and a
concurrent de-methylation of the CD133 promoter [41,42].
Therefore, the acquisition of a mesenchymal-like phenotype and
increased TGFb-signaling may also be responsible for both the
down-regulation of SOX10 and the increase of CD133 mRNA
level. The mutually exclusive expression of SOX10 and CD166 we
observed in MeWo cells upon silencing of CD271 may underpin
this hypothesis.
Further we observed that tumorigenic CD271+ cells capable of
differentiation were maintained in bulk melanoma cell cultures
and were also maintained by the microenvironment of the
xenograft tumor. This ‘‘robustness’’ might indicate the importance
of CD271+ cells for maintaining a viable population. In contrast,
the low occurrence of cell strains comprising CD133+ cells may be
due to a loss upon cell culturing. This loss could be explained by a
decreased differentiation or regeneration of CD133 expressing
cells or may be due to their sensitivity for the microenvironment.
However, by xenotransplantation of CD271+ and CD133+ sorted
cells we could rule out a rapid and intense differentiation of
cultured CD133+ cells as demonstrated by their capability to form
heterogenic tumors like their CD271+ counterpart. Hence, cells of
both fractions fulfilled the criteria of tumor-initiating cells and
evidenced their undifferentiated phenotype and suggest CD133+
and CD271+ being equally tumorigenic. The relatively high
amount of CD133+ and CD271+ cells in unsorted cell populations
seemed sufficient to allow tumor formation that was comparable to
enriched cells. Nevertheless, the observed differences in levels of
differentiation markers like HMB45, MART-1 and MITF-M in
xenograft tumors of CD133+, CD1332 and CD271+ cells was due
to different basal levels of these markers in cells prior to injection.
In contrast to CD271+ cells, the MART-1 and MITF-M levels of
CD133+ cells were indeed much higher as determined by qPCR.
We speculate that CD133+ cells may generate a MART-1
expressing sub-population or turn into a CD133/MART-1 double
positive population in vitro and, to a higher extend, in vivo. In
addition, observations of CD271+/CD133+ cells in all tumors,
irrespective of the initial cells phenotype and the development of
CD133+ tumors from initially CD1332 sorted cells, strongly
suggests the plasticity of melanoma cells. This plasticity is not
necessarily caused by CD133 expression, but could be credited to
the co-expression of CD271. We were unable to exclude that
xenograft tumors developed from CD271 expressing cells rather
than from cells exclusively expressing CD133. This is because in
all experiments we detected cells that shifted from CD271+/
CD1332 to the CD271+/CD133+ phenotype.
The amount of melanoma-initiating cells is expected to be low
in the tumor due to a reduced proliferative capacity and the
tendency to divide asymmetrically [43]. Thus these cells should be
successively lost upon in vitro expansion. We demonstrated, at least
in part, a high quantity of CD271+ cells in melanoma cell cultures,
arguing against their role as melanoma-initiating cells. However,
using dye retention assays we were able to identify slowly-dividing
label-retaining cells as a minor fraction of melanoma cell cultures.
Flow cytometry of isolated dye-retaining cells revealed their
CD271+ phenotype found in independent experiments of two
melanoma cell strains. This finding emphasizes the stem-like
properties of at least a sub-set of CD271+ cells [11,44]. In the
Mel9-1 cell strain we observed the co-occurrence of CD271+,
CD133+ and CD271+/CD133+ cells in the dye-retaining fraction
suggesting the transition of CD271+/CD1332 into CD271+/
CD133+ cells within this fraction. However, we also observed cells
negative for both markers in the fraction of PKH26high sorted
Mel9-1 cells and to a higher extent in dye-retaining Mel4-7 cells.
This and the observation of lower levels of CD271 and CD133 in
cells with a lower retaining capacity suggest the dye-retaining
fraction as being heterogeneous. Therefore label-retention is not
directly linked to expression of CD271 and CD133 but enables the
enrichment of melanoma cells for either of these markers.
inducers SOX8, MYB, ETS1, TFAP2A, TFAP2C and NFkB1 of SOX10 expression by qPCR. Expression levels of shRNA control (shCtl.) cells and CD271k.d.
cells are shown as DDCT values normalized to b-actin and related to shCtl. cells as mean value6 SD of biological triplicates. **p#0.01; ***p#0.001 (t-
test). The scale is logarithmic (log). (F) Scheme of putative CD271-dependent signaling pathways. GSEA and qPCR may point out a connection of
CD271 and a WNT-dependent regulation of TCF/LEF target genes, activation of AP2-dependent target genes like SOX5 that in turn regulates SOX6 or
activation of NFkB signaling.
doi:10.1371/journal.pone.0092596.g007
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Further we demonstrated that CD133+ cells developed from
CD271+ cells in a growth factor reduced environment. With
respect to offered growth factors we observed that the absence of
FGF2 rather than its presence supported the cellular transition
from CD271+/CD1332 to a CD271+/CD133+ phenotype. As this
transition had also occurred spontaneously by CD271+/CD1332
cells that were isolated from a mixed cell culture comprised
CD271+, CD133+ and CD271+/CD133+ cells, we assume a
diverse role of FGF2. FGF2 may alter those signaling pathways
that are already activated in a certain cell population by a specific
mutation or by autocrine or paracrine mechanisms. In the tumor,
FGF2 is secreted by stromal fibroblasts as part of the microen-
vironment [45,46] and may serve either as a stem-cell maintaining
or differentiating factor. As the standard medium, Q263,
contained FGF2, we assume a repression of the transition towards
a CD133+ phenotype that is activated in FGF2 free medium. Yet,
we cannot ultimately decide if the cellular transition was the
consequence of a stress-response triggered by a reduced growth
factor environment or representative of a regenerative mechanism
that ‘‘reactivates’’ dormant cells. The spontaneous transition of
CD271+ sorted melanoma cells towards CD133+ in standard
medium may also depend on the level of TGFb-signaling and
needs both low levels of CD271 and SOX10. We elucidated
whether the level of SOX10 in melanoma cells changed by
treatment with TGFb2 and concomitantly led to expression of
CD133. Indeed, the protein level of SOX10 strongly decreased by
activated TGFb-signaling but levels of CD133 remained un-
changed. In addition, cultivation of cells in hESC-medium led to
increased TGFb-signaling indicated by pSmad2 irrespective
whether FGF2 was present or absent (data not shown). Therefore,
the identification of factors responsible for the transition of
melanoma cells towards a CD133+ phenotype remain elusive and
needs further investigations.
We assume the CD133+ phenotype as a marker of a pre-
differentiated but tumorigenic melanoma cell that derived from a
CD271+ cell as a function of microenvironmental changes. We
further conclude that both cellular states, CD271+ and CD133+,
are tightly controlled and well balanced. This statement is further
underpinned by our observation that the amount of sorted
CD271/CD133 double positive cells decreased in a time-
dependent manner and led to derivation of CD133+/CD2712
cells due to a decreased level of CD271. Overexpression of CD271
or high endogenous levels may promote the stem-like state and
may even keep melanoma cells from differentiation. Therefore a
medium or low endogenous level of CD271 is needed for the
transition towards the CD133+ state. CD271 silencing alleviates
differentiation into a yet unknown cell type and may further
sensitize cells towards drug-induced apoptosis by a reduced DNA-
repair capacity and a decrease of anti-apoptotic genes as observed
by immunofluorescence microscopy and qPCR, respectively.
Therefore, further analyses are needed to fully understand how
CD271 signaling can induce and maintain the stem-like state and
determine melanoma cell properties.
Finally, we analyzed the distribution of CD271+ and CD133+
cells in patient-derived melanoma metastases and observed a
predominance of CD271+ cells whereas expression of CD133 was
less frequently observed. We investigated the expression of both
markers in superficial spreading melanoma and acral lentiginious
melanoma (SSM and ALM; types of cutaneous melanoma) and
uveal melanomas and their respective metastatic sites. We found
CD271 expression in all metastases investigated and respective
xenograft tumors albeit with varying intensities and limited to
tumor-initiating cells [47], negative for HMB45 and MITF. The
mutually exclusive expression of CD271 and differentiation
markers confirms previous findings by Boiko et al., though we
have shown additionally that CD271+ cells persist in xenografted
tumors and primary tumor derived cells strains and may
contribute to the strong heterogeneity we observed among them
by qPCR. The finding of CD133 co-expressed with MART-1 in
primary metastases may support their more differentiated pheno-
type.
Conclusions
We identified CD271 as a predominant molecule in malignant
melanoma responsible for proliferation, tumorigenicity and
plasticity of melanoma cells. The connection of CD271 with the
transcription factor SOX10 points out a CD271/SOX10 network
controlling these properties by yet unknown mechanisms. Addi-
tionally, melanoma cell plasticity linked CD271 to the glioma stem
cell marker CD133 and clearly demonstrated a connection of both
markers in malignant melanoma most likely via a CD271+/
CD133+ intermediate cell state. However, melanoma cells and
melanoma-initiating cells can be described by more than just a
single marker. We cannot exclude that other cell surface markers
like ABCB5 or transcription factors like SOX2 may participate or
even act as critical factors in the transition of melanoma cells
phenotype. Further, this transition may not only depend on
secreted factors supported by the tumor microenvironment but
may also be induced by chemotherapeutics. Taken together, these
findings have strong implications not only for basic melanoma
understanding, but potentially provide a laver to constrict tumor
growth and metastasis.
Materials and Methods
Ethics Statement about Patient-derived material
Written informed consent was obtained from each patient.
Patient’s material was collected between 2010–2012 at the
Comprehensive Cancer Center of the Charite´ University Hospital
(CCCC) with coverage of the Tumor REsearch And Treatment –
20 Patient Pilot (TREAT 20) project approved by the Federal
Ministry of Education and Research (No. 031 5852A). Tumor
specimens were obtained at the time of surgery and spitted into
equal pieces for paraffin-embedding and establishment of tumor-
derived cell cultures. We received material sufficient for both
procedures from 16 out of 20 patients.
Cell culture
All primary low passage melanoma cell strains and A375 cells
were cultured in Quantum 263 medium (PAA, Austria) supple-
mented with 1% Penicillin/Streptomycin (Invitrogen) while
MeWo cells were cultured in Leibovitz’s L-15 medium (Invitrogen)
supplemented with 1% Penicillin-Streptomycin. Cells were
cultured in 5% CO2, 37uC and routinely passaged at 80%
confluence. Medium was changed every 3 days. Human neonatal
epidermal Melanocytes were cultured in Melanocyte growth
medium (both Lonza). Phenotype shift experiments were done in
hESC-medium with and without 4 ng/ml of FGF-2 (Biosource) or
in Quantum 263 medium supplemented for 3 days with 10 ng/ml
TGFb2 (Miltenyi).
Magnetic Cell sorting (MACS)
MACS separation into CD133+ and CD1332 fractions was
done with accordance to the manufacturer’s instructions using the
indirect CD133 MicroBead kit and LS columns (Miltenyi,
Germany). Briefly, 80% confluent cells were washed with PBS
and detached with Accutase (PAA, Austria) and adjusted up to
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46107 cells per column and sorted with a modified PBS buffer
containing 5% FBS (MACS buffer).
Flow cytometry/Fluorescence assisted cell sorting (FACS)
Cells were harvested using Accutase, pelleted at 1000 rpm and
re-suspended in MACS buffer. 2.56105 cells were incubated either
with human specific CD271-PE or CD271-APC antibody
(Miltenyi, clone ME20.4-1.H4, mouse IgG1, 1:20), human specific
CD133 antibody (Miltenyi, clone W6B3C1, mouse IgG1, 1:10,) or
mouse IgG1 Isotype control (Miltenyi) at 4uC for 10 min. Washed
cells were re-suspended in 500 ml PBS and stored on ice or labeled
with a secondary antibody. Cells were incubated in 100 ml buffer
with AlexaFluor488, anti-mouse (Invitrogen).Stained cells were
used for cell sorting or flow cytometry using FACSAria III or
FACScalibur and Accuri C6 (Beckton&Dickinson), respectively.
Data analysis was done with FlowJo software.
Label-retaining assay
Labeling of cells using the fluorescent lipophilic dye PKH26 was
done with accordance to the manufacturer’s instructions. Labeled
cells were re-plated and monitored. Analysis of co-labeling of
PKH26 (PE), CD271 (APC) and CD133 (FITC) was done with
Accuri C6. Analysis of labeled and sorted cells of each cell strain
was performed in at least three independent experiments.
Western-Blot
25 mg–40 mg of total protein lysates were separated on a 8%
SDS-PAGE gel and transferred on a nitrocellulose membrane by
using the iBlot Dry Blotting System (Invitrogen). Membranes were
incubated with primary antibodies (CD271, clone D4B3, XP, Cell
signaling; SOX10, clone 20B7, RnD; CD133, clone C24B9 and b-
Tubulin, clone 9F3 both from Cell Signaling Technology,
Germany; all diluted 1:1000) overnight at 4uC and with a
secondary antibody (goat anti-rabbit IgG LI-COR Biosciences,
USA) for 1 h at RT. Detection was done with the Odyssey
Infrared Imaging System (LI-COR Biosciences, USA).
RNA isolation and RT-PCR
RNA isolation from frozen cell pellets was performed with the
RNeasy Mini Kit (Qiagen, Germany) and from 5 mm FFPE
sections using the RNeasy FFPE Kit (Qiagen), following the
manufacturers protocol. Reverse transcription of 500 ng–2.5 mg
RNA was performed with SuperScript VILO cDNA synthesis kit
(Invitrogen, Germany) and diluted to a final volume of 50 ml.
qRT-PCR was carried out on a Step one plus (Applied Biosystems,
Germany) for 30–40 cycles. Primers were designed for 55–60uC
annealing temperatures (Table S1). In qPCR expression levels
were calculated either with DCT or DDCT, normalized to b-actin.
PCR products (15 ml) were separated on a 2% agarose (BioRad)
gel.
Tumorigenicity
Briefly, a number of 16105–16106 cells was mixed with
Matrigel (1:1) and subcutaneously injected in NSG [48] mice
(n = 3/per group). Tumor volume given as [(tumor width)2 6
tumor length]60.5 was measured with a caliper instrument and
was monitored during the entire experiment with the measure-
ments of two perpendicular tumor diameters.
Ethics Statement about Animal Experiments
All animal experiments were performed at the EPO GmbH,
Berlin, Germany in accordance with the German Animal
Protection Law and approved by the local responsible authorities
(LAGeSo A0452/08). The in vivo procedures were consistent and
in compliance with the UKCCCR guidelines.
Immunohistochemistry and Immunofluorescence
analysis (IF)
FFPE material was sectioned to 2 mm after de-waxing,
peroxidase blocking and antigen-retrieval using citrate buffer,
pH 6.0. IHC for melanoma markers Melanosome (clone HMB45,
mouse, 1:50, Dako); Tyrosinase (clone T311, mouse, 1:50,
Novocastra); MITF (clones C5+D5, mouse, 1:25, Zytomed) and
CD271 (clone D4B3, XP, rabbit, 1:100, Cell signaling), as well as
hematoxylin/eosin (H&E) was done with the Discovery XT
biomarker platform (Ventana). For IF on tumor sections: sections
were blocked in 5% goat serum at RT for 2 h and incubated with
primary antibodies: human specific CD133 (clone W6B3C1,
mouse, 1:10, Miltenyi); CD133 (polyclonal, rabbit 1:100, Biorbyt);
CD271 (clone D4B3-XP, rabbit, 1:100, Cell signaling) and
MART-1 (Melan-A clone A103/M2-7C10/M2-9E3, 1:50,
Zymed) diluted in 2% BSA/PBS. Incubation was done in a wet
chamber overnight at 4uC. Sections washed with PBS/0.1%
Tween-20 were incubated with secondary antibodies Alexa-
Fluor488, anti-rabbit and AlexaFluor594, anti-mouse (both
Invitrogen) for 1 h, at RT. IF on cultured cells: after washing
with PBS and a fixation step (4% PFA in PBS for 10 min at RT),
cells were either permeabilized with 0.1% Triton-X100 for
staining of nuclear proteins or directly blocked with 2% BSA in
PBS. Fixed cells were incubated with primary antibodies (CD271-
PE and CD271-APC, Miltenyi, clone ME20.4-1.H4; SOX10,
clone 20B7, RnD; CD133 Miltenyi, clone W6B3C1; cH2AX
(phosphorylated (Ser139) H2AX, DNA-damage marker) and
pSmad 2 clone 138D4, Cell signaling) overnight at 4uC. Next
day, cells were washed and incubated with secondary antibodies
AlexaFluor488 and AlexaFluor594, anti-rabbit/anti-mouse (both
Invitrogen) and 49,6-Diamidino-2-phenylindole dihydrochloride
(DAPI), (Sigma-Aldrich) for 1 h, at RT, washed and analyzed.
Knock-down and overexpression of CD271
For knock-down of CD271, melanoma cells were transfected
with 2 mg of each shRNA plasmid (#2: 59-ACAACCT-
CATCCCTGTCTATT-39; #3: 59-CCCGAGCACATAGA
CTCCTTT-39 and #4: 59-CCGAGCACATAGACTCCTTTA-
39) or control shRNA (shCtl., 59-GGAATCTCATTCGATGCA-
TAC-39; all from Qiagen) using Lipofectamine2000 (Invitrogen).
Cells were selected with puromycin (10 mg/ml) over a period of
two weeks. For over-expression melanoma cells were stably
transfected with a plasmid expressing GFP-tagged human
CD271 (RG207966, OriGene) and selected with G418 (300 mg/
ml, PAA).
Gene expression profiling
Whole genome expression profiling of CD271k.d. and shCtl.
cells was performed with three biological replicates. Illumina raw
data of BeadChip HumanHT-12V4 platform were summarized
via the BeadStudio without normalization and background
correction. Follow-up processing was done via the R/Bioconduc-
tor environment. The lumi package was used for data annotation.
Following statistical tests, data were quantile normalized.
Accession numbers
The microarray analysis data have been deposited to the NCBI
Gene Expression Omnibus (GEO) with accession number
GSE52456.
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Statistical analysis
Significantly differentially expressed genes were identified by
statistical tests using the bioconductor limma package [49]. The
significance in terms of the false discovery rate (FDR), the q-value,
was determined by the q-value package applied to several
statistical tests (Student’s t-test, Welch test and Wilcoxon test).
Genes were defined significantly differentially expressed when the
average Affymetrix (MAS5) detection p-value of at least one case
(treatment or control) was ,0.05 and one of the p- values of
statistical tests (Student’s t-test, Welch test and Wilcoxon test) was
,0.05. Genes with ratios .1.33 or ,0.75 were defined as
significantly up-regulated or down-regulates, respectively. Heat
maps were generated using Spearman’s rank correlation as
similarity measure and complete linkage. Genes with a limma
false discovery rate (FDR) below (#0.005) were defined as highly
significantly regulated. Using this criteria we found 123 genes
comprising 68 down-regulated (ratio ,0.05) and 55 up-regulated
genes (ratio .20). P-values depicting significance of experimental
values were calculated by Excel using a two-tailed test.
Meta-analysis
Whole genome expression profiling data of SOX10k.d. cells
stored at NCBI GEO, accession number GSE37059 were
processed via the R/Bioconductor environment using statistical
analysis tools mentioned above. Affymetrix chip data were
processed via package affy and normalized with Robust Multi-
array Average (RMA) from the same package. Package limma was
used for making significance tests for differential gene expression.
The results of these tests were adjusted for multiple testing via
package q-value. Data were normalized with Robust Multi-array
Average (RMA). Genes up-regulated (ratio .1.33) and down-
regulated (ratio ,0.75) with an average detection p-value ,0.05
were analysed. Intersection sets were found via gene symbol
annotations.
Gene-Set enrichment Analysis (GSEA)
Quantile normalized expression data of CD271k.d. cells and
shCtl. cells were analysed with the GSEA analyses tool of the
Broad institute (http://www.broadinstitute.org/gsea/index.jsp)
and the molecular signature databases c2.all.v4.0.symbols.gmt
(curated gene sets) and c3.all.v4.0.symbols.gmt (motif gene sets).
Supporting Information
Figure S1 The knock-down of CD271 induces strong
changes in cellular morphology and gene-expression. (A)
Knock-down of CD271 in melanoma cells led to strong
morphological changes indicated by rearrangement of the marker
CD166 (ALCAM) as determined by immunofluorescence micros-
copy. Nuclei were stained with DAPI (blue), scale bars indicate
50 mm. Phase contrast (PH) depicts cellular morphology. (B)
Deceleration of growth of melanoma cells stably transfected with
shRNA plasmids #2, #3 or #4 (16105 cells plated). Cell counts
6 SD of n= 3 experiments are shown. (C) Clustering of 7895
differentially regulated genes among biological triplicates of shCtl.
vs. CD271k.d. cells (shRNA#4) depicts 4048 (51.3%) down-
regulated and 3874 (48.7%) up-regulated genes. By more stringent
criteria these numbers changed to 68 down-regulated and 55 up-
regulated genes. (D) Immunofluorescence microscopy of melano-
ma cells stably transfected with either shRNA plasmids #2, #3
and #4 or shRNA control (shCtl.) revealed efficient silencing of
CD271 (upper panels) as well as a strong down-regulation of
SOX10 (center panels) and FOXD3 (lower panels) by shRNA #3
and #4. Note the nuclear localization of SOX10 and FOXD3 in
shCtl. and sh#2 cells and diffuse or absent staining in sh#3 and
sh#4 stably transfected cells, respectively. Representative areas
are shown. Nuclei were stained with DAPI (blue), scale bars
indicate 50 mm. (E) Western blot of 25 mg of whole cell extracts of
untransfected (Mock) or shRNA plasmid transfected cells for
CD271 and SOX10. A representative out of three is shown.
Tubulin served as loading control. (F) Melanoma cells that were
stably transfected with a CD271 expression plasmid (CD271exo)
showed an inverse correlation of CD271 and CD133. Shown are
DDCT values normalized to b-actin and related to expression
levels in Mock cells as mean value 6 SD of biological triplicates.
(TIF)
Figure S2 CD271k.d. cells show increased DNA-damage
and decreased expression of anti-apoptotic genes. (A)
qPCR for expression levels of CD271, CD133, SOX10, SOX2,
ERBB3 and FOXD3 in MeWo cells stably transfected with shRNA
plasmids #2, #3 or #4. Expression levels of shRNA control
(shCtl.) cells and of cells transfected with CD271-targeting shRNA
plasmids are shown as DDCT values normalized to b-actin and
related to shCtl. cells as mean value 6 SD of biological triplicates.
The scale is logarithmic (log). (B) Immunofluorescence microscopy
of MeWo cells transfected with either a shCtl. plasmid or
shRNA#4 plasmid for CD271 and SOX10 reveal strong
expression or efficient down-regulation of both proteins, respec-
tively. Phase contrast (PH) depicts cellular morphology. (C)
Immunofluorescence microscopy of MeWo cells transfected with
shRNA plasmid #4 (sh#4) for SOX10 and CD166 showing their
mutually exclusive expression. A representative out of three is
shown. (D) Analysis of mRNA expression levels of anti-apoptotic
genes cIAP1 (BIRC2), cIAP2 (BIRC3) and BCL-2 in melanoma
cells stably transfected with either shCD271 plasmids (sh#2,
sh#3, sh#4) or shRNA control (shCtl.) by qPCR. mRNA
expression levels are shown as DDCT values normalized to b-
actin and related to shCtl. cells as mean values 6 SD of biological
triplicates. *p#0.05; **p#0.01; ***p#0.001 (t-test). (E) Detection
of DNA-damage in melanoma cells transfected with either a shCtl.
plasmid or shRNA plasmids #3 and #4 by immunofluorescence
microscopy for cH2AX (arrows). In (C) and (E) Nuclei were
stained with DAPI (blue), scale bars indicate 50 mm.
(TIF)
Figure S3 CD271 but not CD133 is frequently expressed
on melanoma cells. (A–D) Flow cytometry of 10 patient-
specific melanoma metastases-derived cell strains as well as (E) cell
lines A375 and MeWo. Results show presence of distinct CD271+
and CD133+ populations in % or in % 6 SD of biological
triplicates. Mouse IgG1 served as isotype control. Tumor
metastases represent three entities LN (n= 3); SKIN (n= 5);
PUL (n = 2). Cell lines MeWo and A375 were established from a
LN or SKIN metastasis, respectively. (F) Detection of CD133
protein level in CD133+ and CD1332 MACS-enriched cells by
western blot analysis. Tubulin served as loading control.
(TIF)
Figure S4 Slowly-dividing melanoma cells are dye-
retaining. (A) Immunofluorescence microscopy of melanoma
cells (Mel9-1 and Mel4-7) for expression of CD271 or CD133,
respectively. Nuclei were stained with DAPI (blue), scale bars
indicate 50 mm. (B–C) PKH26 in dye-retaining cells 7 days and 14
days after labeling. Phase contrast (PH) depicts cellular morphol-
ogy. Scale bars indicate 50 mm. (D) Corresponding isotype
controls depict negative cells for analysis of dye-retaining cells
for presence of CD271 and CD133.
(TIF)
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Figure S5 CD271+ cells re-establish cellular heteroge-
neity in vitro. (A) FACS-plot indicates the distribution of
CD271+, CD133+ and CD271+/CD133+ cells before FACS, the
area of CD271+ cells is highlighted (red border, left panel).Yield of
CD271+ FACS-sorted cells determined by flow cytometry after
sorting (center panel) in comparison to mouse IgG1 isotype control
(right panel). (B) Immunofluorescence microscopy of CD271+
cells, 3 days after sorting for expression of CD133 and CD271. (C)
Amount of cells analyzed in (B). Bars indicate mean values 6 SD
of n= 8 counts. (D) Isolation of CD271/CD133 double positive
cells (red rectangle) by FACS (center panel). Re-analysis of sorted
and cultured cells after 7 days shows the derivation of CD133+/
CD2712 cells from CD271/CD133 double positive cells. (E)
Summary of flow cytometry results shows presence of cells in
distinct CD271+ and CD133+ or CD271/CD133 double positive
or double negative sub-fractions indicating the time-dependent
increase of CD133+ cells. Sub-sets are represented as % 6 SD of
biological triplicates. Mouse IgG1 served as isotype control. ***p#
0.001 (t-test). (F) Analysis of PKH26-labeled double positive cells
following 3 days and 7 days of isolation by immunofluorescence
microscopy reveals the presence of dye-retaining cells.
(TIF)
Figure S6 TGFb represses SOX10 expression in mela-
noma cells. (A) Validation of cellular plasticity with a different
melanoma cell strain. Cells were sorted either for a CD271+/
CD1332 phenotype or absence of both markers. (B) Flow
cytometry of cells following isolation and cultivation after 3 days
for cellular sub-sets proves the re-establishment of the cellular
heterogeneity of the initial cell culture irrespective of their
phenotype. (C) Phase contrast images of unsorted and sorted cells
depict their specific cellular morphology. (D) Verification of flow
cytometry results by immunofluorescence microscopy. Single and
double positive cells were observed in the cell culture 3 d after
sorting. (E) Immunofluoresecence microscopy of shCtl. cells
untreated (Ctl.) or treated with TGFb2 (10 ng/ml) for 3 days for
levels of phospho-Smad 2 (pSmad2) depicting active TGFb-
signaling, SOX10 and CD133. TGFb2-treatment led to a strong
decrease of SOX10 whereas CD133 was not affected. Nuclei were
stained with DAPI (blue), scale bars indicate 50 mm.
(TIF)
Figure S7 CD271 and differentiation markers are
mutually exclusive expressed in melanoma metastases.
(A) Summary of patient cohort, tumor site, first metastasis and
final metastasis. ALM: acral lentiginous melanoma; SSM:
superficial spreading melanoma; UVE: uveal melanoma; MUC:
mucosal melanoma. LN: lymph node; HEP: hepatic; PUL: lung;
SKIN: cutaneous metastases. The table also sums up the
expression of markers from IHC. (B) Mutually exclusive
expression of CD271 and differentiation markers TYR, HMB45
and MITF in cutaneous and (C) hepatic metastases as indicated.
(TIF)
Figure S8 Comparison of melanoma metastases and
xenograft tumors. (A) Comparison of a primary metastasis
(PM) of patients T20/19 and (B) T20/20 and the corresponding
xenografted tumor (PMX) for presence and localization of CD271
and MITF shows the mutually exclusive expression of these
proteins in both tumor entities, marked by the red dashed line. (C)
Heterogeneity was also established by cultured cells of patient
T20/02 upon tumor formation. Expression patterns of CD271
and MITF are comparable to those observed in the primary
metastasis. Scale bars indicate 50 mm.
(TIF)
Figure S9 TGFb1 induced genes are enriched in
CD271k.d. cells. (A–B) Comparison of data sets of shCtl. and
CD271k.d. cells with data sets of murine mammary epithelium cells
(NMuMG cells) after stimulation with TGFb1 [53] by gene-set
enrichment analysis (GSEA). GSEA revealed the enrichment of
TGFb1 induced genes like CTGF, SMAD7, TGIF and SERPINE1
upon CD271 silencing.
(TIF)
Table S1 qPCR primers. Primers were designed with primer
quest at http://eu.idtdna.com/site with an average of 22 bp and
an annealing temperature of 60uC yielding in products of 150–
250 bp. Details about qPCR can be found in the materials and
methods section.
(DOCX)
Table S2 Statistics of grown Tumors. The volume of
tumors, grown subcutaneously in NSG mice was determined once
a week.
(DOCX)
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